Mainz Biomed Partners with Quest Diagnostics for Cancer Screening Trial

Mainz Biomed N.V. has announced a partnership with Quest Diagnostics to support the clinical trials of its ColoAlert test for early colorectal cancer detection. Quest will provide laboratory services for the ReconAAsense study, involving approximately 15,000 participants across the United States, aimed at obtaining FDA validation for the test.

The ColoAlert test utilizes PCR technology to analyze DNA from stool samples, showing promising results in early cancer detection. Should the FDA approve the test, Quest would have the option to commercialize the kit with semi-exclusive rights for 18 months.

This collaboration could address the significant gap in colorectal cancer screening in the U.S. market, estimated at over $4 billion. Mainz Biomed's CEO, Guido Baechler, highlighted Quest's role in making innovations accessible to patients.